Cocrystal Pharma Inc
NASDAQ:COCP
Cocrystal Pharma Inc
NASDAQ:COCP
Price:
1.5
USD
-1.96%
Market Closed
Market Cap:
$20.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
US |
|
Oncternal Therapeutics Inc
NASDAQ:ONCT
|
US |
|
D
|
Duncan Engineering Ltd
BSE:504908
|
IN |
|
Haitian International Holdings Ltd
HKEX:1882
|
CN |
|
S
|
Shenzhen International Holdings Ltd
HKEX:152
|
HK |
|
J
|
Jiangsu Tongli Risheng Machinery Co Ltd
SSE:605286
|
CN |
|
WuXi Xinje Electric Co Ltd
SSE:603416
|
CN |
|
G
|
GTM Holdings Corp
TWSE:1437
|
TW |
|
E
|
Excite Holdings Co Ltd
TSE:5571
|
JP |
|
Gibus SpA
MIL:GBUS
|
IT |
|
A
|
Aryt Industries Ltd
TASE:ARYT
|
IL |
|
G
|
Gezinomi Seyahat Turizm Ticaret AS
IST:GZNMI.E
|
TR |
|
Japan Steel Works Ltd
OTC:JPSWY
|
JP |
|
Menicon Co Ltd
TSE:7780
|
JP |
|
HES Technology Group Co Ltd
SZSE:002963
|
CN |
|
Cosmopolitan International Holdings Ltd
HKEX:120
|
HK |
|
Next eGO BV
OTC:EGOXF
|
DE |
|
Lee's Pharmaceutical Holdings Ltd
HKEX:950
|
HK |
Multiples-Based Value
The Multiples-Based Value of one
COCP
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 1.5 USD,
Cocrystal Pharma Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
COCP Multiples-Based Value
LOCKED
Multiples Across Competitors
COCP Competitors Multiples
Cocrystal Pharma Inc Competitors
Cocrystal Pharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
19.6m USD | 0 | -2 | -1.2 | -1.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
855.1B USD | 13.1 | 41.4 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.7B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
229B GBP | 5.2 | 29.7 | 16.4 | 23.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.8B USD | 4.5 | 16 | 9.9 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.8B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.6B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| UK |
|
GSK plc
XETRA:GS71
|
99.8B EUR | 2.7 | 15.2 | 8.2 | 10.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
